TrumpRx was not designed for most Americans who obtain prescription drugs through insurance, according to Chris Klomp, the federal official then leading the Center for Medicare. His description narrowed a platform that the White House had promoted as a major drug-price breakthrough.
Speaking at STAT's Breakthrough Summit East on March 19, 2026, Klomp said the goal was not “some massive reach.” He cited 170 million commercially insured Americans and 68 million Medicare beneficiaries, then said the remaining population was largely covered by Medicaid and the Children's Health Insurance Program.
“TrumpRx is not for most of them, it's cash pay,” Klomp said. That sentence defines the platform more precisely than claims about transforming prescription prices for the entire health system.
Klomp Drew a Line Between Cash Pay and Insurance
Cash pay means that a patient buys a medicine outside an insurance benefit and pays the listed or discounted out-of-pocket price. TrumpRx can therefore offer a lower route for a listed product without changing what an employer plan, Medicare plan, Medicaid program or CHIP program covers.
Klomp's population figures were not estimates of how many people would use TrumpRx. They were his explanation for why the platform was intentionally narrower than the insured market. STAT also reported that he rejected the suggestion that the administration's drug policies amounted to price caps.
The distinction matters because a platform price and an insured patient's cost are different measures. The interview did not establish that TrumpRx would lower premiums, alter formularies, remove prior authorization or reduce every beneficiary's pharmacy bill.
The February Launch Covered a Defined Drug List
The White House launched TrumpRx.gov on February 5 with products from AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer, the first five manufacturers named as having reached most-favored-nation pricing agreements with the administration.
The launch fact sheet said 40 branded medicines were available initially. Depending on the manufacturer and product, a patient with a valid prescription could obtain savings through a downloadable or printable coupon, or through a manufacturer channel linked from the government website.
The administration published examples that included diabetes and obesity medicines, fertility drugs, inhalers and insulin lispro. Those examples were product-specific cash prices. They did not demonstrate a uniform percentage reduction across all prescriptions or all patients.
Insurance Integration Was a Separate Proposal
A White House release issued the day after launch said the platform was especially relevant to people facing high out-of-pocket costs for medicines not fully covered by insurance. For people obtaining prescriptions through insurance, the same release called on Congress to pass a broader health plan.
That proposed legislation was described as a way to codify most-favored-nation savings and enable health-plan coverage of TrumpRx purchases. The appeal to Congress confirms that the initial cash-pay website and insurance coverage were not the same policy mechanism.
Nothing in Klomp's quoted comments established how many users would save money, what their average savings would be or how the platform compared across all existing discount channels. Those questions require transaction and utilization data, not launch-price examples.
A Narrow Tool Should Be Judged on Narrow Claims
TrumpRx may offer meaningful savings when a listed cash price is below the amount a patient would otherwise pay. That usefulness can be measured drug by drug and purchase by purchase. It does not make the platform a systemwide solution for prescription affordability.
Klomp's intervention replaced a universal promise with a testable one. The relevant questions are which medicines are listed, what cash price is actually available, how many purchases occur and how those prices compare with patients' alternatives.
The platform should not be credited with changing insurance benefits that it did not initially include. Nor should its cash discounts be dismissed merely because their reach is limited. The evidence-based position is simpler: TrumpRx launched as a defined cash-pay channel, and its performance should be judged within that boundary.